BridgeMD
Tests treatment safety and results for Liver Failure
Official title Safety and Tolerability Study of a Novel Bioartificial Liver in Liver Failure and Small-for-Size Syndrome
ClinicalTrials.gov ID: NCT07312864
What this study is testing
What is Chemically induced pluripotent stem cells biological Artificial Liver?
Chemically induced pluripotent stem cells biological Artificial Liver is an investigational medicine, being studied as a potential treatment for liver failure.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to evaluate the safety and tolerability of a novel bioartificial liver (CiPS-BAL) in patients with liver failure or small-for-size syndrome. The study will also collect preliminary data on clinical outcomes and laboratory parameters during treatment.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults
You may be able to join if
- Patients diagnosed with liver failure (including acute, subacute/acute-on-chronic, and chronic liver failure) or small-for-size syndrome
You likely can't join if
- Presence of severe extrahepatic systemic end-stage diseases
- Uncontrollable infection or active bleeding
- Pregnant or breastfeeding women
- History of allergy or known severe hypersensitivity to CiPSC-derived cell products or blood products
- Peripheral vascular collapse leading to inability to obtain venous access or collect blood
- Unable or unwilling to provide informed consent or unable to comply with study requirements
See the full eligibility criteria
- Patients diagnosed with liver failure (including acute, subacute/acute-on-chronic, and chronic liver failure) or small-for-size syndrome
- Presence of severe extrahepatic systemic end-stage diseases
- Uncontrollable infection or active bleeding
- Pregnant or breastfeeding women
- History of allergy or known severe hypersensitivity to CiPSC-derived cell products or blood products
- Peripheral vascular collapse leading to inability to obtain venous access or collect blood
- Unable or unwilling to provide informed consent or unable to comply with study requirements
- Unwilling to receive CiPSC-based therapy
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, not specified. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.